Pembrolizumab KEYNOTE-001: an adaptive study leading to accelerated approval for two indications and a companion diagnostic

Sunyu Kang, Eric H. Rubin, Gregory M. Lubiniecki et al.|Annals of Oncology|2017

Cited by 106